Overexpression of RACK1 Predicts Poor Prognosis in Melanoma

Abstract

Melanoma is a highly malignant skin cancer with limited treatment options, the mechanism of the occurrence and development of melanoma is still unclear till now. Receptor for activated C kinase 1 (RACK1) is a scaffolding protein that mediates multiple signaling pathways; it interconnects distinct signaling pathways to control essential cellular processes. RACK1 was reported as an oncogene in human tumorigenesis, but little is known about its role in melanoma. This study aimed to investigate the expression of RACK1 in patients with melanoma and to reveal its possible functions in melanoma cells. The expression profiles of RACK1 detected in tumor tissues from melanoma patients showed that RACK1 was higher in tumor tissues, and its expression level was well associated with the clinical progression of melanoma (TNM stage, P=0.009). Furthermore, RNA interfering (RNAi) knockdown of RACK1 could efficiently suppress the proliferation, migration and invasion of A375 and A875 cells and promote their apoptosis. Taken together, these results suggest that RACK1 may be a poor prognostic factor in human melanoma, and it may be a new therapeutic target for melanoma treatment.

PHB2 promotes tumorigenesis via RACK1 in non-small cell lung cancer

“…RACK1 was found to be downregulated and act as a tumor suppressor in gastric cancer 17 . In contrast, RACK1 was found to be upregulated and contribute to tumorigenesis in breast cancer 18 , hepatocellular carcinoma 19 , melanoma 20 , pulmonary adenocarcinoma 21 , 22 , pancreatic ductal adenocarcinoma 23 , and neuroblastoma 24 . Thus, RACK1 is considered to be a crucial factor affecting the development and progression of cancer.…”

The postbiotic sodium butyrate synergizes the antiproliferative effects of dexamethasone against the AGS gastric adenocarcinoma cells

“…Dex treatment ( Table 4 ) potentially downregulated the receptor of activated protein C kinase 1 ( RACK1 ) gene expression. The overexpression of RACK1 was associated with cancer progression and poor prognosis ( 77 ). RACK1 upregulation was reported to promote cancer progression via the NF-κB pathway (by increasing the M2/M1 macrophage ratio) in oral squamous cell carcinoma previously ( 78 ).…”

RACK1 promotes the occurrence and progression of cervical carcinoma

“…It serves as a multifunctional scaffold protein and plays a functional role in a multiple of biological responses, including growth, migration and invasion of tumor cells 8,10 . There is evidence indicating that RACK1 is up‐regulated in multiple tumor types and is considered as a promising marker in hepatocellular carcinoma, oral squamous cell carcinoma, melanoma, breast cancer, and non‐small cell lung cancer 11–15 . As a matter of fact, several limited articles reported the role of RACK1 in CC in recent years 16,17 ; however, due to the mechanisms of RACK1 involved in CC may be multifaceted, more available data are needed to elucidate its function and evaluate its clinical value in CC.…”

“… 8 , 10 There is evidence indicating that RACK1 is up‐regulated in multiple tumor types and is considered as a promising marker in hepatocellular carcinoma, oral squamous cell carcinoma, melanoma, breast cancer, and non‐small cell lung cancer. 11 , 12 , 13 , 14 , 15 As a matter of fact, several limited articles reported the role of RACK1 in CC in recent years 16 , 17 ; however, due to the mechanisms of RACK1 involved in CC may be multifaceted, more available data are needed to elucidate its function and evaluate its clinical value in CC. Therefore, the aim of this study was to investigate the role of RACK1 in the occurrence and progression of cervical cancer.…”